Detection_NN
of_IN
estrogen_NN
receptor_NN
variants_NNS
in_IN
endometrium_NN
,_,
myometrium_NN
,_,
leiomyoma_NN
and_CC
peripheral_JJ
blood_NN
mononuclear_JJ
cells_NNS
:_:
comparison_NN
to_TO
variants_NNS
present_JJ
in_IN
breast_NN
cancer_NN
._.

Oestradiol_NN
has_VBZ
mitogenic_JJ
and_CC
regulatory_JJ
effects_NNS
on_IN
various_JJ
organs_NNS
and_CC
cells_NNS
,_,
mediated_VBN
mainly_RB
by_IN
its_PRP$
nuclear_JJ
receptor_NN
-LRB-_-LRB-
ER_NN
-RRB-_-RRB-
._.

The_DT
presence_NN
of_IN
aberrant_JJ
ER_NN
forms_NNS
in_IN
Oestrogen-dependent_JJ
tumors_NNS
has_VBZ
been_VBN
discussed_VBN
in_IN
correlation_NN
with_IN
tumor_NN
progression_NN
._.

ER_NN
variants_NNS
,_,
generated_VBN
by_IN
alternative_JJ
splicing_NN
,_,
have_VBP
been_VBN
detected_VBN
in_IN
human_JJ
breast_NN
cancer_NN
,_,
but_CC
also_RB
in_IN
normal_JJ
mammary_JJ
glands_NNS
,_,
therefore_RB
their_PRP$
role_NN
in_IN
tumorigenesis_NN
has_VBZ
been_VBN
questioned_VBN
._.

We_PRP
have_VBP
investigated_VBN
,_,
by_IN
the_DT
use_NN
of_IN
the_DT
reverse_JJ
transcription_NN
polymerase_NN
chain_NN
reaction_NN
amplification_NN
technique_NN
,_,
the_DT
possible_JJ
existence_NN
of_IN
ER_NN
variants_NNS
in_IN
other_JJ
normal_JJ
estrogen_NN
target_NN
organs_NNS
and_CC
cells_NNS
,_,
such_JJ
as_IN
uterus_NN
-LRB-_-LRB-
myometrium_NN
and_CC
endometrium_NN
-RRB-_-RRB-
,_,
in_IN
peripheral_JJ
blood_NN
mononuclear_JJ
cells_NNS
and_CC
in_IN
a_DT
benign_JJ
uterus_NN
tumor_NN
-LRB-_-LRB-
leiomyoma_NN
-RRB-_-RRB-
._.

We_PRP
have_VBP
detected_VBN
variant_JJ
ER_NN
in_IN
these_DT
samples_NNS
and_CC
have_VBP
compared_VBN
the_DT
variant_JJ
profile_NN
to_TO
that_DT
observed_VBN
in_IN
breast_NN
cancer_NN
._.

All_DT
tissues_NNS
and_CC
cells_NNS
studied_VBN
expressed_VBD
both_CC
wild-type_JJ
ER_NN
and_CC
variant_JJ
species_NNS
._.

Variant_JJ
forms_NNS
encompassed_VBD
ER_NN
with_IN
deletions_NNS
of_IN
exons_NNS
2_CD
,_,
5_CD
and_CC
7_CD
._.

Variants_NNS
with_IN
exon_NN
5_CD
deleted_VBN
were_VBD
detected_VBN
only_RB
in_IN
peripheral_JJ
blood_NN
mononuclear_JJ
cells_NNS
and_CC
in_IN
breast_NN
cancer_NN
._.

Variants_NNS
with_IN
exons_NNS
2_CD
and_CC
7_CD
deleted_VBN
were_VBD
present_JJ
in_IN
all_DT
specimens_NNS
tested_VBN
._.

These_DT
results_NNS
corroborate_VBP
previous_JJ
findings_NNS
that_IN
the_DT
presence_NN
of_IN
ER_NN
variants_NNS
is_VBZ
not_RB
a_DT
characteristic_NN
of_IN
breast_NN
cancer_NN
._.

The_DT
physiological_JJ
significance_NN
and_CC
possible_JJ
clinical_JJ
relevance_NN
of_IN
the_DT
variant_JJ
ER_NN
forms_NNS
remain_VBP
to_TO
be_VB
elucidated_VBN
._.

